Clinical Trial

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Study acronym: LANTIMA
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total Corabotase doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-10-30 -> 2029-03-30 2026-05-06
minor Completion pushed: 2027-10-30 -> 2029-03-30 2026-05-06
Trial Details
NCT Number NCT04752774
Lead Sponsor Ipsen
Conditions Spasticity
Enrollment 240 participants
Start Date 2021-04-29
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28